• PO, IV: Treatment of invasive aspergillosis (tablets and injection).
• PO, IV: Prevention of invasive Aspergillus and Candida infections in patients who are severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy (tablets, oral suspension, delayed-release oral suspension, and injection).
• PO: Treatment of oropharyngeal candidiasis (including candidiasis unresponsive to itraconazole or fluconazole) (oral suspension).

Contraindicated in:

• Hypersensitivity to posaconazole or other azole antifungals
• Concurrent use of atorvastatin, ergot alkaloids, lovastatin, pimozide, quinidine, simvastatin, or sirolimus
• Concurrent use of venetoclax at initiation and during the ramp-up phase
• Hereditary fructose intolerance (for delayed-release oral suspension only).

Use Cautiously in:

• History of/predisposition to QTc prolongation including congenital QTc prolongation, concurrent medications that prolong QTc, or electrolyte abnormalities (hypokalemia, hypomagnesemia); correct pre-existing abnormalities prior to administration
• Moderate to severe renal impairment (CCr <50 mL/min); use only if justified by risk/benefit assessment (IV form should be avoided, use oral form only)
• Severe diarrhea, vomiting, or renal impairment (monitor for breakthrough fungal infections)
• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Children <18 yr (IV) or <13 yr (oral) (safety and effectiveness not established).

CV: QT interval prolongation, TORSADES DE POINTES.

Endo: adrenal insufficiency.

F and E: hypokalemia, hypomagnesemia, hypocalcemia.

GI: diarrhea, nausea, vomiting, HEPATOCELLULAR DAMAGE, PANCREATITIS.

Neuro: headache.

Resp: cough.

Misc: fever, HYPERSENSITIVITY REACTIONS.

Drug-Drug:

• May ↑ cyclosporine, sirolimus, and tacrolimus levels and risk of toxicity; use with sirolimus contraindicated; for cyclosporine and tacrolimus, ↓ dose initially and monitor levels frequently.
• May ↑ quinidine and pimozide levels and the risk for arrhythmias; concurrent use contraindicated.
• May ↑ levels and risk of toxicity from ergot alkaloids, including ergotamine and dihydroergotamine; concurrent use contraindicated.
• May ↑ levels of simvastatin, atorvastatin, or lovastatin and the risk for rhabdomyolysis; concurrent use contraindicated.
• May ↑ risk of tumor lysis syndrome, neutropenia, and serious infection during initiation or the ramp-up phase of venetoclax in patients with chronic lymphocytic leukemia or small lymphocytic leukemia; concurrent use contraindicated.
• Rifabutin, phenytoin, cimetidine, and efavirenz may ↓ levels and may ↓ effectiveness; avoid concurrent use.
• Esomeprazole and metoclopramide may ↓ levels and effectiveness.
• May ↑ rifabutin levels and risk of toxicity; avoid concurrent use.
• QT interval prolonging drugs may ↑ risk for QT interval prolongation and torsades de pointes; avoid concurrent use.
• May ↑ digoxin levels and risk of toxicity; monitor levels frequently.
• May ↑ phenytoin, midazolam, ritonavir, and atazanavir levels and risk of toxicity; monitor for excess clinical effect.
• May ↑ levels of and risk of neurotoxicity, syndrome of inappropriate antidiuretic hormone, and paralytic ileus with concurrent use of vinca alkaloids, including vincristine and vinblastine; consider using an alternative nonazole antifungal.
• May ↑ levels and risk of adverse cardiovascular reactions to calcium channel blockers; consider dosage reduction.

(Generic available)

• Delayed-release tablets: 100 mg;
• Oral suspension (cherry flavor): 40 mg/mL;
• Solution for injection: 18 mg/mL;

Treatment of Invasive Aspergillosis

• PO (Adults and Children 13 yr): Delayed-release tablets: 300 mg twice daily on Day 1, then 300 mg once daily starting on Day 2 for a total of 6–12 wk.
• IV (Adults and Children 13 yr): 300 mg twice daily on Day 1, then 300 mg once daily starting on Day 2 for a total of 6–12 wk.

Prophylaxis of Invasive Aspergillus and Candida Infections

• PO (Adults and Children 13 yr): Oral suspension: 200 mg 3 times daily. Duration of therapy is based on recovery from neutropenia or immunosuppression.
• PO (Adults and Children 2 yr and >40 kg): Delayed-release tablets: 300 mg twice daily on Day 1, then 300 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.
• IV (Adults): 300 mg twice daily on Day 1, then 300 mg once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.
• IV (Children 2 yr): 6 mg/kg (max = 300 mg) twice daily on Day 1, then 6 mg/kg (max = 300 mg) once daily starting on Day 2. Duration of therapy is based on recovery from neutropenia or immunosuppression.

Treatment of Oropharyngeal Candidiasis

• PO (Adults and Children 13 yr): Oral suspension: 100 mg twice daily on Day 1, then 100 mg once daily for the next 13 days. For refractory oropharyngeal candidiasis, give 400 mg twice daily; duration of therapy is based on the severity of the patient’s underlying disease and clinical response.

Noxafil

• Blocks ergosterol synthesis, a major component of fungal plasma membrane.

• Fungistatic/fungicidal action against susceptible fungi.

Spectrum:

• Aspergillus spp.,
• Candida spp.

Therapeutic Classification: antifungals

Pharmacologic Classification: triazoles

Absorption: Well absorbed following oral administration; absorption is optimized by food; IV administration results in complete bioavailability.

Distribution: Extensive extravascular distribution and penetration into body tissues.

Protein Binding: >98%.

Metabolism/Excretion: Some metabolism via UDP glucuronidation; 66% eliminated unchanged in feces, 13% in urine (mostly as metabolites).

Half-life: 35 hr.

Posanol

(plasma concentrations)

• Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Instruct patient to take posaconazole during or immediately (within 20 min) following a full meal or liquid nutritional supplement in order to enhance absorption. Take missed doses as soon as remembered.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
• Advise patient to notify health care professional if severe diarrhea or vomiting occurs (may ↓ posaconazole levels and allow breakthrough fungal infections) or if signs and symptoms of liver injury (itching, yellow eyes or skin, fatigue, flu-like symptoms) or change in HR or rhythm occur.
• Rep: May cause fetal harm. Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during therapy.

po-sa-KON-a-zole

NDC Code^*

• 0085- Merck Sharp and Dohme Corp.
  • 0085-1328- NOXAFIL
    • 0085-1328-01- 1 BOTTLE, GLASS in 1 CARTON (0085-1328-01) > 105 mL in 1 BOTTLE, GLASS

• 0085- Merck Sharp and Dohme Corp.
  • 0085-4324- NOXAFIL
    • 0085-4324-02- 60 TABLET, COATED in 1 BOTTLE (0085-4324-02)

• 0085- Merck Sharp and Dohme Corp.
  • 0085-4331- NOXAFIL
    • 0085-4331-01- 1 VIAL, GLASS in 1 CARTON (0085-4331-01) > 16.7 mL in 1 VIAL, GLASS

• 0254- Par Pharmaceutical Inc.
  • 0254-2045- POSACONAZOLE
    • 0254-2045-02- 60 TABLET, COATED in 1 BOTTLE (0254-2045-02)

• 0527- Lannett Company Inc.
  • 0527-2133- POSACONAZOLE
    • 0527-2133-35- 60 TABLET, DELAYED RELEASE in 1 BOTTLE (0527-2133-35)

• 0527- Lannett Company Inc.
  • 0527-2133- POSACONAZOLE
    • 0527-2133-43- 1000 TABLET, DELAYED RELEASE in 1 BOTTLE (0527-2133-43)